KAUST’s 6.7-Gram Microneedle Patch Tracks Drug Levels in Real Time

A lightweight wearable developed at King Abdullah University of Science and Technology (KAUST) can continuously follow the concentration of a medicine beneath the skin and send the readings to a smartphone. The 6.7-gram research prototype combines microneedles, electrochemical sensing, onboard electronics and Bluetooth in a single patch.

From snapshots to a continuous curve

Medicines with a narrow therapeutic window must remain within a concentration range that is high enough to work but low enough to avoid toxicity. Monitoring commonly relies on a blood sample sent to a laboratory, producing a useful but isolated snapshot. Concentrations may change between samples because of dose timing, kidney function, metabolism and interactions with other medicines.

The KAUST patch reaches interstitial fluid immediately beneath the skin through an array of tiny needles. Its sensors convert chemical measurements into electrical signals, while miniaturized electronics process and transmit the data. The team demonstrated the system with vancomycin, a potent antibiotic whose dosing often requires careful therapeutic monitoring.

What was demonstrated

According to KAUST and the study published in Device, the integrated platform tracked changing vancomycin concentrations over several hours in laboratory and preclinical experiments. A connected smartphone displayed the measurements in near real time. The work is notable not because microneedle sensing is entirely new, but because the researchers integrated sensing, processing, wireless communication and visualization into a small wearable platform.

Continuous curves could eventually show clinicians whether a medicine is entering or leaving the body faster than expected. In principle, the sensing chemistry could also be adapted to other drugs that demand close dose control, supporting more individualized therapy.

Important limitations

The patch is not yet a clinical device and should not be used to change a dose. Results collected over hours in controlled and preclinical conditions do not establish reliable performance over days on diverse human skin. Sweat, motion, temperature, inflammation, sensor fouling and differences between interstitial-fluid and blood concentrations may all affect readings.

Future studies must demonstrate calibration against standard laboratory assays, long-term stability, biocompatibility, sterilization, secure wireless handling of health data and dependable manufacturing. Regulators would also need evidence that acting on continuous readings improves outcomes rather than creating false alarms or inappropriate dose changes. The breakthrough is an integrated proof of feasibility—not a replacement for therapeutic drug monitoring today.